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Objectives. To evaluate the effects of different local hemostatic agents in a new high flow vascular experimental bleeding
model.
Design. Bovine thrombin combined with collagen matrix (bTcM), microporous polysaccharide hemospheres (MPH), freeze-
dried rFVIIa with and without the combination of MPH were compared to a control group (solely compression) in a ran-
domized fashion (20 animals/group). Primary endpoint was hemostasis, and secondary endpoints were time to hemostasis,
blood loss, and blood pressure at hemostasis.
Methods. The common carotid artery of heparinized rats was ligated proximally and transected. Compression was
applied for one minute followed by application of the topical hemostatic agent. Compression was maintained for another
two minutes followed by re-evaluation of hemostasis: if bleeding continued additional compression was applied and there-
after bleeding was checked every minute until hemostasis.
Results. All animals in the bTcM group obtained hemostasis compared to 20% in the control group (p< 0.0001). The
combination of MPH and rFVIIa (70% hemostasis) also showed a significant hemostatic capacity compared to control
group (p< 0.001). None of the other active treatment groups differed compared to control group. Animals treated with
bTcM had a significantly shorter time to hemostasis compared to animals in the other active treatment groups. No signif-
icant difference in blood loss and blood pressure at hemostasis was detected.
Conclusions. The most effective hemostatic agent was bTcM, followed by the combination of rFVIIa and MPH, while
neither MPH nor rFVIIa alone displayed any hemostatic capacity compared to compression only.
Keywords: Local hemostasis; Bovine thrombin; Microporous polysaccharide hemispheres; Recombinant FVIIa.Introduction
Correct surgical technique is a prerequisite for success-
ful vascular surgery. Inadequate hemostasis can jeopar-
dize the outcome of a procedure. In spite of immaculate
technique, hemostatic problemsmay require the use of
adjuvant topical hemostatic sealing. In recent years an
abundance of topical hemostatic agents have become
commercially available.
The sealing products are usually a preparation of
a procoagulant substance with a combination of a ve-
hicle such as exogenous thrombin and collagen matrix
(e.g. FloSeal, Baxter, USA). The thrombin is either
derived from human plasma, or of animal origin;
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available for this indication.
Another principle for topical hemostasis is the use of
a matrix, such as oxidized cellulose or gelatin sponges,
which activates and provides a template for the endog-
enous coagulation cascade to obtain hemostasis.1 A
different matrix has recently been made available:
microporous polysaccharide hemospheres (purified
starch, Traumadex, Medafor, USA). The starch is
able to absorb fluid from the blood that leads to con-
centration of the endogenous coagulation factors and
platelets, which in turn facilitate hemostasis. Systemic
use of recombinant FVIIa (NovoSeven, NovoNordisk,
Denmark), originally developed for the treatment of
hemophilia patients,2 has been used successfully off-
label to decrease bleeding in trauma patients.3
All hemostatic agents have their clinical shortcom-
ings, however, there is an absence of objective data
and comparative studies between modern topical
hemostatic agents in a clinical vascular surgicalerved.
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perform since the cause of bleeding can be diverse,
i.e. the origin of the bleeding may be arterial, venous
or oozing. Further, the presence or absence of concom-
itant anticoagulation/antiplatelet therapy may differ,
and blood pressure variation, possible acidosis or
hypothermia may further cloud the picture. All these
factors influence bleeding considerably and make
the interpretation of clinical data a considerable
challenge.
Therefore we have focused on a new and vali-
dated experimental model in the rat to simulate
high flow vascular bleeding. The aim of the study
was to evaluate the local hemostatic effect of a
preparation of bovine thrombin combined with a
collagen matrix (bTcM ), and to compare it withEur J Vasc Endovasc Surg Vol 33, March 2007microporous polysaccharide spheres (MPH) and top-
ical rFVIIa alone and in combination in a randomized
experimental setting.
Material and Methods
Animals
Adult acclimatized Sprauge-Dawley rats were used.
The model development, validation and the compara-
tive study was performed in accordance to the guide-
lines of good laboratory practice and approved by
the Local University Ethics Committee for Animal
Experiments.Total amount of animals: 154
Animals in validation
study: 54
Animals evaluated with
femoral bleeding: 8
Animals evaluated with
carotid bleeding: 46
Animals with
retrograde carotid
bleeding: 16
Animals with
antegrade carotid
bleeding: 30
Animals enrolled and
randomized in the
comparative study: 100
Solely
compression: 
Randomized: 20 
Received
randomized
treatment: 20 
Analyzed: 20 
BTcM:
Randomized: 20 
Received
randomized
treatment: 20 
Analyzed: 20 
MPH: 
Randomized: 20 
Received
randomized
treatment: 20 
Analyzed: 20 
rFVIIa:
Randomized: 20 
Received
randomized
treatment: 19 
Did not receive 
treatment: 1
Animal did not 
survive
anesthesia
Analyzed: 19 
MPH + rFVIIa:
Randomized: 20 
Received
randomized
treatment: 20 
Analyzed: 20 
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There are several bleeding models described in the
literature. Parenchymal bleeding models have been
used in rat, rabbit and swine.4e7 Injuries to the groin
by transection of the femoral vessels in swine have
been used in models simulating battlefield trauma.8,9
Arterial anastomotic leakage has been experimentally
simulated in various aortic anastomoses in
rabbits.10,11
The aim of our experimental study was to compare
different local hemostatic agents in a model imitating
a common hazard in vascular surgery: high pressure
bleeding from the suture line or stitch holes in anasto-
moses or patches where additional sutures are diffi-
cult to place and compression by itself may be
inadequate. Our purpose was to create a high flow ar-
terial bleeding model, which would be repeatable and
standardized, with an endpoint variability that was
within acceptable limits.
An arterial transection in the rat simulates the
above-mentioned bleeding well. To avoid a laparot-
omy, which is likely to cause hypothermia and thus
affect coagulation, we focused on two extra abdomi-
nal arteries with suitable dimensions for our purpose:
the common femoral and carotid arteries. We
evaluated retrograde and antegrade bleeding from
these locations in 54 animals with respect to the fre-
quency of obtaining hemostasis, time to hemostasis
and blood loss (data not shown). Bleeding from the
femoral artery presented larger variation and was
less repeatable than bleeding from the common
carotid artery. The femoral artery bleeding model
was therefore disregarded. The common carotid ar-
tery is a larger vessel and easily accessible. The carotid
bifurcation is distal to the mandible and the common
carotid artery is of a technically acceptable length and
facilitates repeatable transections in the middle,
between the clavicle and at the bifurcation of the ves-
sel. Of the 54 animals, 46 were evaluated with carotid
transections. Retrograde bleeding of the carotid artery
was the most suitable model since the bleeding is
severe and continuous and is not immediately fatal.
We found that the model fulfilled the objective criteria
postulated, and it was clearly effective for a high
throughput in vivo assay.
Experimental studies of endarterectomies in the
common carotid artery have revealed that without
heparin the majority of the animals develop thrombi
in the damaged vessel.12,13 In our validation of tran-
section of the common carotid artery, 80% of the ani-
mals obtained hemostasis on solely compression,
without heparin administration. Thus we were re-
quired to heparinize the animals to create a negativecontrol group and obtain repeatable results. We also
wanted to imitate the clinical situation of vascular sur-
gery, where all patients are heparinized. Reviewing
the literature of experimental bleeding models, we
found the dose of heparin administered in different
settings was variable. Doses between 200 and
2000 IU/kg have been used,4e6,10,11 but such a high
dose in an experimental model must be cautiously ex-
trapolated to the clinical setting. Two different doses
of unfractionated heparin, 150 and 300 IU/kg were
validated in our model. The two doses did not pro-
duce any difference in measured bleeding parameters,
and gave a consistent and reproducible prolongation
of Activated Clotting Time (ACT). Thus we continued
to work with the lower dose (150 IU/kg bw).
No differences in parameters studied, except body
weight were noticed between male and female rats
during our validation. Due to their more convenient
larger size (larger blood volume, larger vessel size),
we chose to perform the comparative study with
only male rats.
To ensure that bovine thrombin had the intended
effect in rat plasma, we performed a dilution series
with plasma from five rats and the bovine thrombin
used in bTcM. The response in the activated pro-
thrombin time assay was dose dependent and gave
a reproducible foreshortening (data not shown).
The comparative study
Study design
Five different treatment groups (20 animal/group)
were evaluated. All animals were treated with com-
pression of the bleeding site (the distal part of the
transected common carotid artery) for one minute,
and then the topical agent was administered in a ran-
domized fashion. Compression was reapplied for two
minutes and possible hemostasis was evaluated. Fur-
ther compression was repeated and controlled every
minute until hemostasis was obtained.
(1) Control group e solely compression: compression
was applied with cotton covered application sticks
and swabs.
(2) Combination of bovine thrombin and a collagen
matrix (bTcM, Floseal, Baxter Inc, USA). bTcM
was prepared and used according to the directions
provided the by manufacture. One ml of the high
viscosity suspension was used for each animal.
(3) Microporus Polysaccharide Hemospheres (MPH,
Traumadex, Medafor Inc, USA) were used ac-
cording to the directions provided by the manu-
facture. One ml of the powder was used for each
animal.Eur J Vasc Endovasc Surg Vol 33, March 2007
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Nordisk A/S, Denmark) was used in freeze-dried
form and it was topically applied at the bleeding
site. 0.2 mg of the powder, which is 1/3 ml of the
uncompressed freeze-dried powder, was used
per animal.
(5) Combination of MPH and rFVIIa. A mixture of 1/
3 ml of the freeze-dried rFVIIa and 2/3 ml of MPH
were used per animal.
The doses of the hemostatic agents were chosen for
practical reasons; 1 ml of bTcM and MPH was a suit-
able amount of agent that fits in the operating area,
and it also resembles the clinical situation well. Re-
combinant FVIIa has to our knowledge not been
used in freeze-dried form as a topical hemostatic
agent. The optimal dose for rFVIIa in this setting is
unknown. The dose we evaluated in this study was
clearly supraphysiological at the actual bleeding site.
The strategy of using freeze-dried rFVIIa topically
should be looked upon as a possible proof of concept.
The primary endpoint evaluated was hemostasis,
and the secondary endpoints included analysis of
time to hemostasis, blood loss, blood pressure at
time of hemostasis and rebleeding.
One hundred animals (median weight: 322 g, iqr:
145 g) were included in the study, and randomized
to separate treatment groups. Block randomization
was used. One block contained five animals, one ani-
mal for each treatment group. In total there were
twenty blocks, and twenty animals in each treatment
group. The randomization (sealed envelopes) was
performed after the surgical exposure was completed.
One surgeon (KB) performed all the evaluations of
bleeding parameters.
Standard operating procedure
Theacclimatizedanimalswereadministereda subcuta-
neous injection of neurolept anesthesia, utilizing amix-
ture of Hypnorm (0.135 mg/ml fentanyl citrate &
10 mg/ml fluanisone, Janssen Pharma Inc, Belgium)
and Midazolam Hameln (5 mg/ml, Pharma Hameln,
GmbH). The experimental animals never regained
consciousness. Rats who survived the bleeding
evaluations were euthanized intravenously with an
overdose of phenobarbiturate acid and ethanol.
The animals were placed on a heat pad in a supine
position with spontaneous respiration. Rectal tem-
perature was measured at the start and end of the
operation. One groin was opened and the femoral
vessels were dissected, ligated distally and catheter-
ized (PE-50, Becton Dickson Inc, USA). The arterial
catheter was used for blood pressure measured by
Powerlab (AD-instruments Inc, UK). The venousEur J Vasc Endovasc Surg Vol 33, March 2007catheter was used for administration of unfractio-
nated heparin (500 IU/ml, Løvens A/S, Denmark)
and saline.
A skin incision was made above the clavicle, and
the right common carotid artery was dissected proxi-
mal to the carotid bifurcation. Three drops of papav-
erine sulphate (40 mg/ml, Recip AB, Sweden) was
administered topically on the vessel to prevent
spasm. Unfractionated heparin 150 IU/kg was given
iv and allowed to equalize for one minute before the
start of the experiment. The artery was then ligated
caudally and transected with scissors, and conse-
quently the artery bleed retrograde from the cranial
portion.
All animals were treated with compression on the
transected artery with gentle pressure using a wooden
cotton covered applicator stick (SelefaTrade AB,
Sweden) for one minute. For exact placement of the
stick a microscope was used with 10e20 times magni-
fication (Leica, Wild M650, GmbH). The topical agent
was then administered in a randomized fashion.
Compression was reapplied with a clean non woven
swab (SelefaTrade AB, Sweden) 5 5 cm, folded twice
into 2.5 2.5 cm, and kept in place by digital pressure
for two minutes. Possible hemostasis was then evalu-
ated and if necessary compression was repeated and
controlled every minute until hemostasis was ob-
tained. If the swab was soaked in blood another one
was held firmly on top and changed if soaked
through. To keep the local hemostatic agent in place
at the transection, the innermost compress was not
changed during observation. The pressure on the
swab was evaluated under the microscope to ensure
that it was firm enough to maintain hemostasis
without compromising the spontaneous breathing.
Bleeding time was measured from transection of
the artery until hemostasis by ocular verification
using a microscope (Leica, Wild M650, GmbH). If
the animal continued to bleed after twenty minutes
of observation primary hemostasis was considered
not to be achieved and euthanasia was performed.
If the animal achieved hemostasis within twenty
minutes possible rebleeding was checked after an-
other five minutes. Blood loss was measured by the
corrected weight of the cotton covered applicator stick
and the swabs. The actual bleeding weight was then
related to the weight of the animal to correct for differ-
ent animal weights, which in small animal affect total
blood volume and the possible amount of bleeding.
The unfractionated heparin induced anticoagula-
tion level was monitored using Activated Clotting
Time (ACT, Hemocrone Jr, Int Technodyne Corp,
USA). It was measured as a baseline and at the end
of the procedure.
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The size of the study groupswere calculated to confirm
a 20% difference of the primary endpoint. Descriptive
data are expressed as median and interquartile range.
Since the distribution of datawas skewednonparamet-
ric analysis was performed using variance analysis ac-
cording to Kruskal-Wallis between several groups and,
when appropriate, Mann-Whitney U-test for unpaired
data between groups andWilcoxon signed rank-test for
paired data within groups. For contingency tables chi-
square and Fishers exact test were used. A p-value of
<0.05 was considered significant and all test were
two-tailed. The software StatView 5.0 (Abacus Con-
cepts, USA) was used.
Results
One animal in the rFVIIa-group died prematurely and
was excluded from the analyses. All other animals
survived anesthesia and surgery. Dissection related
blood loss was negligible. The overall operation time
was approximately one hour from beginning of anes-
thesia to the end of the experiment. The body temper-
ature increased (approximately 0.4 C) significantly in
all animals during the procedure regardless of
whether hemostasis was achieved or not.
The activated clotting time was prolonged at the
end of the procedure between 2.5e3 times the base-
line values (data not shown).
The overall analysis for the primary endpoint he-
mostasis (Fig. 1) was significant ( p< 0.0001) and the
group treated with bTcM was superior. In the bTcM-
group all animals obtained hemostasis, whereas only
1/4 of the animals in the control group (compression)
ceased to bleed ( p< 0.0001). The animals treated with
MPH or rFVIIa did not significantly differ from each
other or the control group. The hemostatic effect
was significantly improved ( p< 0.001) when MPH
and rFVIIa were combined and compared to thecontrol group. When the hemostatic capacity of the
combination of MPH and rFVIIa was compared to
bTcM a significant difference ( p¼ 0.02) was observed
in favor of the bTcM treatment.
Time to hemostasis (Fig. 2); there was a significant
overall treatment effect (p¼ 0.0005). The animals in
the bTcM group had the shortest time to hemostasis
(median 5 min. 15 s, iqr 3 min. 40 s), which was signif-
icantly shorter compared to the animals in all the
other active treatment groups.
There was no significant difference between the
treatment groups with respect to the amount of
weight adjusted blood loss during the experiment
(Fig. 3).
Mean arterial blood pressure before the transection
of the carotid artery was 88 mmHg (iqr: 15.5 mmHg)
for all animals. In Fig. 4 the blood pressure before
transection and at the time of hemostasis is shown.
There was no significant difference between the dif-
ferent treatment regimes. As anticipated, pair wise
comparison between the baseline value and the
mean arterial pressure at the time of hemostasis
revealed that the APB dropped in all animals irres-
pective of treatment group.
Rebleeding did not occur in the four animals in the
control group that received hemostasis. In the other
groups rebleeding did occur (bTcM: 5/20, MPH: 3/8,
rFVIIa: 1/4, MPHþrFVIIa 2/14), albeit the frequency
of rebleeding was not statistically significant between
the active treatment groups. Five of the rebleedings
were fatal; three animals in the MPH, one in the bTcM
and one in the rFVIIa group respectively.
Discussion
Clinical comparative studies of topical hemostatic
agents are as discussed above challenging to interpret.
Many of theses factors can only be reduced andHemostasis
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Fig. 1. Primary Endpoint: diagram presenting animals obtaining hemostasis or continuing to bleed throughout the 20 min
observation time. Only animals treated with bTcM or the combination MPH and rFVIIa were significantly superior to solely
compression.Eur J Vasc Endovasc Surg Vol 33, March 2007
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an in vivo experimental setting remains challenging,
since the natural variability in all bleeding models is
considerable.
During the validation work of the present experi-
mental model both advantages and disadvantages of
the model were revealed. Due to the anatomic limita-
tions at the bleeding site, and the profuse bleeding
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Fig. 3. Secondary endpoint blood loss (median and inter-
quartile range) presented as a ratio of the measured blood
loss divided with the bodyweight of the animal. Only ani-
mals, which obtained hemostasis, are included in the
diagram.
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Fig. 2. Secondary endpoint: time to hemostasis; individual
animals that obtained hemostasis are depicted as filled
circles, whereas animals that did not receive hemostasis
are depicted with open circles. Numbers of animals are lim-
ited (<5) in the two groups receiving solely compression
(control group) and rFVIIa. The bTcM treated animals had
a significantly shorter time to hemostasis compared to the
other active treated animals.Eur J Vasc Endovasc Surg Vol 33, March 2007from the carotid artery, the precise administration of
the hemostatic agents must be performed with great
care. To avoid asphyxia in the animal, compression
of the bleeding site must be executed cautiously, espe-
cially when the extra volume of the local hemostatic
agent is added. Although we used a microscope (6e40
times magnification) it is at times surprisingly diffi-
cult to determine the exact time when the hemorrhage
gradually diminished and finally ceased. Moreover,
the variability becomes greater if more than one
person is involved in the assessment of the bleeding.
In attempt to reduce this variability only one surgeon
did the assessments in the present study.
A further limitation of the present study is that it
could not be performed blinded. Local hemostatic
agents have recognizable different physical proper-
ties; these differences prevented us from doing
a blinded study. We chose the block randomization
design to minimize potential bias.
The number of animals in each treatment group (20
rats) was adequate to evaluate the primary endpoint
with confidence, the interpretations of the secondary
endpoints should be done cautiously since a limited
number of animals in most treatment regimes got
hemostasis and were assessable.
Rebleeding was confirmed by ocular inspection in
the microscope, which contrary to the termination of
bleeding was easily defined when fresh blood
appeared in the previously dry transection area. An
unanticipated 25% of the bTcM group rebleed. There
is no obvious explanation for this lack of clot stability,
and this interesting observation requires further stud-
ies, which are currently underway in our laboratory.
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Fig. 4. Median arterial blood pressure in all animals prior
to transection of the carotid artery compared to the animals
obtaining hemostasis. All animals got the anticipated pres-
sure fall after transection but no significant difference
was identified between the treatment groups at the time of
hemostasis.
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pressure lower than the prebleeding pressure, re-
ceived after the five minutes observation time, resus-
citation with saline until blood pressure normalized.
The aim was to evaluate the stability of the hemostatic
clot. Whether the saline itself contributed to any he-
mostatic deficiency is not possible to evaluate from
this study, but it cannot be ruled out. The limited sam-
ple size made the resuscitation maneuver difficult to
evaluate. It seems, however, that if hemostasis was
obtained, the clot was stable to the increased blood
pressure.
Various studies of local sealants have been made in
recent years.4e11,14e17 Most often fibrin sealants have
been compared to cellulose pads and collagen dress-
ings, with and without thrombin of various origins.
Fibrin sealants have been superior to all other prepa-
rations at all endpoints assessed.4,5,10,11,15,17 Fibrin
containing preparations have to be applied on a dry
surface, which is not always preferable or even possi-
ble to obtain in reality. We wanted to evaluate sealants
that interact with the endogenous coagulation, and do
not require a dry surface to be effective.
Although several different agents are commercially
available, the optimal remains to be found. Such an
optimal agent should possess certain qualities. Obvi-
ously the hemostatic agent should effectively stop
various types of bleedings irrespective of the presence
of anticoagulation/antiplatelet therapy. In the present
study bTcM and the combination of MPHþrFVIIa
were clearly able to stop the experimental vascular
surgical bleeding (100 and 70% respectively). bTcM
has been evaluated in animal models10 and in vascu-
lar, cardiovascular and spinal surgery studies, and it
has proved to be a reliable haemostatic agent,14,18,19
which our study confirms.
Ideally the procoagulant factor should be of a syn-
thetic or recombinant orgin. Using a bovine coagula-
tion factor causes an immunologic risk of developing
autoantibodies to human coagulation factors, and
potentially causing an iatrogenic hemophilia/throm-
bophilia. Such antibodies are awell-recognized clinical
hazard.20e22 Tominimize or avoid such an immunolog-
ical problem would be to use a human plasma derived
procoagulant factor. Interestingly the thrombin used in
bTcM for theNorthAmericanmarket is plasmaderived
whereas it is still of bovine origin in Europe. But using
human plasma derived coagulation factors have the
well-known risk of virus transfection.
For the above reasons rFVIIa seemed especially
attractive to evaluate in this setting. The adjunctive
intravenous administration of rFVIIa has recently
proved capably of significantly reducing blood loss
in severe blunt trauma patients in an internationalmulticenter randomized placebo controlled double
blind clinical study.23 Recombinant FVIIa has also
recently been reported to significantly decrease trans-
fusion in a retrospective consecutive single center
clinical study of intractable bleeding.24 In our study
topical application of only rFVIIa was not beneficial,
whereas the combination of MPH and rFVIIa signifi-
cantly improved the primary endpoint hemostasis.
This may indicate that rFVIIa requires a vector or
matrix to be effective as a local hemostatic agent.
MPH has been studied in traumatic models in
swine that involves transection of the femoral vessels.
No difference in any endpoint compared to traditional
pressure dressing could be registered,9 which is in
accordance with our results. Another study evaluated
MPH in partial nephrectomies in swine, and animals
treated with MPH had a shorter bleeding time and re-
duced blood loss compared to cellulose pads.7 This is,
however, contrary to our results, but in the partial
nephrectomy study the MPH was applied with a spe-
cial suction applicator and it is unclear whether the
animals were heparinized or not. We observed a clear
hemostatic capacity with MPH when it was combined
with rFVIIa. Another potential way of increasing the
efficiency of the MPH would be to add a fibrinolytic
inhibitor such as tranexamic acid or add crystallized
calcium ions to the MPH powder since physiologic
coagulation requires the presence of calcium.
Several practical features of the topical hemostatic
agents also should be considered, such as the prepara-
tion time of the agent, the shelf life and economical
aspects. From this point of view MPH has a distinct
advantage compared to both bTcM and rFVIIa. The
physical properties of the agent are also important;
it should be easy to apply correctly. Subjectively we
considered the physical properties of bTcM to be
more appealing compared to MPH. In our hands in
the present model, MPH was less straightforward to
apply and tended to dislodge while maintaining pres-
sure on the bleeding site. On the other hand, the time
for preparation of bTcM is a shortcoming.
In conclusion, in the present experimental random-
ized comparative study of different local hemostatic
agents in a vascular surgical bleeding model, we
were clearly able to show that bTcM (FloSeal, Baxter,
USA) was capable of obtaining hemostasis whereas
MPH (Traumadex, Medafor, USA) was no better
than solely compression. If MPH was combined
with local application of freeze dried recombinant
FVIIa (NovoSeven, NovoNordisk, Denmark) the
hemostatic efficacy was significantly better than com-
pression, MPH alone and rFVIIa alone. It remains un-
certain to what extent MPH is the ideal vector/matrix
for rFVIIa, and further studies are required to find theEur J Vasc Endovasc Surg Vol 33, March 2007
370 K. Bjo¨rses and J. Holstmatrix that is most suitable for rFVIIa. These data
need to be confirmed in other vascular surgical bleed-
ing models where animals not only are heparinized,
but also are treated with platelet inhibitors and sub-
jected to hypothermia and/or acidosis before clinical
recommendations can be given.
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